-5%
Ceritinib is a kinase inhibitor that primarily targets ALK but also inhibits other kinases, such as the insulin-like growth factor 1 receptor (IGF-1R), the insulin receptor (InsR), and ROS1. It blocks ALK autophosphorylation, downstream STAT3 phosphorylation, and proliferation of ALK-dependent cancer cells.
Ceritinib is prescribed for adult patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive, as determined by an FDA-approved test. Always follow the advice of a registered healthcare professional.
